2023
bioRxiv

Therapy Development for Microvillus Inclusion Disease using Patient-derived Enteroids

Authors:

Meri Kalashyan, Krishnan Raghunathan, Haley Oller, Marie-Bayer Theres, Lissette Jimenez, Joseph T Roland, Elena Kolobova, Susan J Hagen, Jeffrey D Goldsmith, Mitchell D Shub, James R Goldenring, Izumi Kaji, Jay R Thiagarajah

Keywords:

Myosin Vb, transporter, enteroids, chloride, Notch, anti-diarrheal, brush-border

Abstract:

Microvillus Inclusion Disease (MVID), caused by loss-of-function mutations in the motor protein Myosin Vb (MYO5B), is a severe infantile disease characterized by diarrhea, malabsorption, and acid-base instability, requiring intensive parenteral support for nutritional and fluid management. Human patient-derived enteroids represent a model for investigation of monogenic epithelial disorders but are a rare resource from MVID patients. We developed human enteroids with different loss-of function MYO5B variants and showed that they recapitulated the structural changes found in native MVID enterocytes. Multiplex Immunofluorescence imaging of patient duodenal tissues revealed patient-specific changes in localization of brush border transporters. Functional analysis of electrolyte transport revealed profound loss of Na ⁺ /H ⁺ exchange (NHE) activity in MVID patient enteroids with near-normal chloride secretion. The chloride channel-blocking anti-diarrheal drug, Crofelemer, dose-dependently inhibited agonist-mediated fluid secretion. MVID enteroids exhibited altered differentiation and maturation versus healthy enteroids. Inhibition of Notch signaling with the γ-secretase inhibitor, DAPT, recovered apical brush border structure and functional Na ⁺ /H ⁺ exchange activity in MVID enteroids. Transcriptomic analysis revealed potential pathways involved in the rescue of MVID cells including serum- and glucocorticoid-induced protein kinase 2 (SGK2), and NHE regulatory factor 3 (NHERF3). These results demonstrate the utility of patient-derived enteroids for developing therapeutic approaches to MVID.